• Structure-Based Screening Reveals NSP15 Inhibitors in SARS-C

  2026-05-09

  This study identifies thymopentin and oleuropein as potent inhibitors of the SARS-CoV-2 NSP15 endoribonuclease using structure-based virtual screening and molecular dynamics simulations. The findings provide key insights for antiviral drug discovery targeting viral immune evasion mechanisms and highlight computational approaches as valuable tools for rapid inhibitor identification.

• γ-Glu-Cys: Powering Next-Gen Glutathione & Peptide Research

  2026-05-08

  This expert deep-dive explores how gamma-Glu-Cys (γ-Glu-Cys) enables innovation in glutathione metabolism, plant stress adaptation, and kokumi peptide engineering. Integrating mechanistic insights and recent evidence, we provide translational researchers with actionable strategies, protocol guidance, and a forward-looking vision for leveraging γ-Glu-Cys—showcasing APExBIO’s high-purity substrate as a pivotal tool. Distinct from standard product listings, this article bridges biochemistry, food science, and biotechnology, spotlighting both the experimental nuances and the broader impact of γ-Glu-Cys-driven workflows.

• Coronavirus Macrodomain Counters PARP-Mediated Antiviral Res

  2026-05-08

  This study demonstrates that the coronavirus macrodomain is essential for evading poly (ADP-ribose) polymerase (PARP)-mediated inhibition of viral replication and for limiting host interferon expression. These findings clarify how specific host PARPs, particularly PARP12 and PARP14, restrict mutant coronavirus propagation, providing mechanistic insight into virus-host interplay and highlighting avenues for targeted research.

• SGC-CBP30: Precision CREBBP/EP300 Inhibition for Epigenetic

  2026-05-07

  Explore how SGC-CBP30, a selective CREBBP/EP300 bromodomain inhibitor, empowers advanced epigenetics and cancer biology research. Discover unique assay insights and translational implications from recent super-enhancer studies.

• Phenylmethanesulfonyl Fluoride (PMSF): Precision in Protein

  2026-05-07

  Phenylmethanesulfonyl fluoride (PMSF) empowers researchers to achieve uncompromising protein integrity during extraction and Western blot preparation. Leveraging insights from COVID-19 macrophage models, this article details actionable protocols, troubleshooting, and advanced applications for robust serine protease inhibition.

• LDH Cytotoxicity Assay Kit: Precision Cell Damage Quantifica

  2026-05-06

  The LDH Cytotoxicity Assay Kit enables precise cell cytotoxicity measurement by detecting LDH released from compromised cells. This non-radioactive assay offers reliable quantification for apoptosis detection, supporting applications from cancer research to nanomaterial biocompatibility assessment.

• SMYD2 Inhibition Attenuates Cisplatin-Induced Renal Fibrosis

  2026-05-06

  This study demonstrates that pharmacological inhibition of SMYD2, using agents such as LLY-507, significantly mitigates renal fibrosis and inflammation in a cisplatin-induced chronic kidney disease model. These findings highlight SMYD2 as a promising epigenetic target for fibrosis intervention and suggest mechanistic links to Smad3/STAT3 pathways.

• Trifluoperazine 2HCl: Applied Workflows for Dopamine D2 Inhi

  2026-05-05

  Trifluoperazine 2HCl stands out as a high-affinity dopamine D2 receptor inhibitor, enabling precise modulation of dopaminergic signaling in both neuropharmacology and immuno-oncology research. This article delivers actionable protocols, workflow enhancements, and troubleshooting strategies—maximizing experiment reproducibility and cross-domain insights.

• PLGA Nanoadjuvant Enhances Mucosal Immunity in Chick H9N2 Va

  2026-05-05

  This study introduces a PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) that substantially improves both mucosal and systemic immunity in chicks vaccinated against H9N2 avian influenza. The work demonstrates the importance of intestinal targeting and sustained antigen release for effective IgA-mediated defense, with implications for next-generation vaccine design.

• EPZ-6438 in Translational Epigenetic Cancer Research: Mechan

  2026-05-04

  Explore the advanced mechanistic role of EPZ-6438 as a potent EZH2 inhibitor in epigenetic cancer research. This in-depth analysis reveals how recent breakthroughs and practical assay guidance elevate experimental design beyond standard workflows.

• Flumequine: Potent DNA Topoisomerase II Inhibitor for Resear

  2026-05-04

  Flumequine is a chemically defined, small-molecule DNA topoisomerase II inhibitor widely used in DNA replication research. Its high purity, specificity, and consistent IC50 value make it a benchmark tool for in vitro studies involving DNA damage and repair. This article details its validated applications, protocol parameters, and limitations.

• C. difficile Responses to Human Mucus: Insights from IEC Co-

  2026-05-03

  This study introduces a novel primary human intestinal epithelial cell (IEC) co-culture system that models physiologic mucus and enables detailed analysis of Clostridioides difficile's transcriptomic, metabolic, and behavioral adaptations to the mucus barrier. The findings reveal that IEC-derived mucus promotes C. difficile growth and induces distinct metabolic shifts and biofilm formation, offering a refined understanding of pathogenesis in the absence of microbiota.

• Metformin HCl Inhibits Achilles Tendon Ossification via Nr4a

  2026-05-02

  This study elucidates how Metformin Hydrochloride suppresses heterotopic ossification in mouse Achilles tendon by downregulating the Nr4a1/Wnt/β-catenin signaling axis. The findings reveal a novel non-metabolic mechanism for metformin, highlighting its potential in bone biology and pathological ossification research.

• Q-VD-OPh: Advanced Pan-Caspase Inhibition in Apoptosis Resea

  2026-05-01

  Q-VD-OPh sets the benchmark for selective, irreversible pan-caspase inhibition across diverse experimental models, enabling precise dissection of apoptotic pathways. This guide spotlights practical workflows, troubleshooting strategies, and translational use-cases—backed by recent mechanistic insights and protocol-level data.

• Thiamet G: Applied O-GlcNAcase Inhibition for Advanced Assay

  2026-05-01

  Thiamet G, a potent O-GlcNAcase inhibitor from APExBIO, enables precise modulation of O-GlcNAcylation for translational research in neurodegeneration, oncology, and placental disease. This guide delivers actionable protocols, troubleshooting, and experimental insights that maximize data quality across diverse cell and animal models.

15594 records 1/1040 page Next 12345 下5页 Last page